|
|
Clinical effect of Qili Qiangxin Capsules modulating Toll-like receptors in the treatment of patients after acute myocardial ischemia and reperfusion |
SHAO Liang1 ZHANG Ping2 CAI Xin-yong1 XIAO Bin1 MEI Song-bei1 |
1.Department of Cardiology,Jiangxi Provincial People′s Hospital,Nanchang 330000,China;
.Department of Neurology,Jiangxi Provincial People′s Hospital,Nanchang 330000,China |
|
|
Abstract Objective To study the value of Qili Qiangxin Capsules modulating Toll-like receptors in improving cardiac function in patients after acute myocardial ischemia (MI) and reperfusion. Methods A total of 100 patients after acute MI and reperfusion treated in the Department of Cardiology in Jiangxi Provincial People′s Hospital from January 2017 to December 2018 were selected as subjects.They were divided into control group and observation group according to the random number table method,50 cases in each group.In the control group,standard therapy was used,while in the observation group,standard treatment combined with Qili Qiangxin Capsules was adopted.The cardiac function indicators like N-terminal pro brain natriuretic peptide (NT-proBNP),left ventricular ejection fraction (LVEF),left ventricular end-systolic diameter (LVESD),left ventricular end-diastolic diameter (LVEDD) and inflammatory factors such as chemokines IP-10 (IP-10),interleukin-8 (IL-8),tumor necrosis factor-α (TNF-α) were compared in the two groups.Results Before treatment,there were no significant differences in LVEF,LVESD,LVEDD,and NT-proBNP between the two groups (P>0.05).After treatment,LVEF in both groups was higher than that before treatment,LVESD,LVEDD and NT-proBNP in both groups were lower than those before treatment,the differences were statistically significant(P<0.05).After treatment,the LVEF of the observation group was higher than that of the control group,the LVESD,LVEDD and NT-proBNP of the observation group were lower than those of the control group,the differences were statistically significant (P<0.05).Before treatment,there were no significant differences in IP-10,IL-8 and TNF-α between the two groups (P>0.05).After treatment,IP-10,IL-8 and TNF-α in both groups were lower than those before treatment,the differences were statistically significant (P<0.05).After treatment,the IP-10,IL-8 and TNF-α in the observation group were all lower than those of the control group,the differences were statistically significant (P<0.05).Conclusion Qili Qiangxin Capsules can inhibit the expression of inflammatory factors by regulating Toll-like receptors,so as to improve the cardiac function of patients after acute MI and reperfusion,which is worthy of promotion.
|
|
|
|
|
[1] |
朱瑞卿,王悦喜.Toll 样受体参与心肌缺血再灌注损伤的研究进展[J].心脑血管病防治,2015,15(3):224-226.
|
[2] |
Yamamoto T,Tsutsumi N,Tochio H,et al.Functional assessment of the mutational effects of human ⅠRAK4 and MyD88 genes[J].Mol Immunol,2014,58(12):66-76.
|
[3] |
Hally KE,La Flamme AC,Larsen PD,et al.Platelet Toll-like receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction[J].Thromb Res,2017,158(5):8-15.
|
[4] |
黄文东,杨艳芳,高琦,等.丹参川芎嗪对离体大鼠心肌缺血/再灌注损伤的保护作用[J].中国医药科学,2019,9(5):9-13.
|
[5] |
罗维昊,贺建东,韩冲芳.糖原合成酶激酶-3 与线粒体分裂蛋白在减轻大鼠心肌缺血再灌注损伤作用中的关系[J].中国当代医药,2018,25(17):12-15.
|
[6] |
王媛媛,曹建,万建华.间歇性低氧在大鼠心肌缺血/再灌注损伤中的保护机制[J].中国当代医药,2018,25(1):4-7.
|
[7] |
李凌华,左英,汪君,等.芪苈强心胶囊治疗慢性心力衰竭的疗效及对脑钠素和血清炎性因子的影响[J].陕西中医,2015,15(7):824-825.
|
[8] |
高雅芬,马骏.Toll 样受体4 与心肌缺血再灌注损伤研究的进展[J].心肺血管病杂志,2018,12(6):590-593.
|
[9] |
刘达燕,文世荣,刘玺印.芪苈强心胶囊对慢性心力衰竭患者心功能和血浆脑钠肽的影响[J].中国药物与临床,2017,17(8):1182-1184.
|
[10] |
Olivares-Silva F,Landaeta R,Aranguiz P,et al.Heparan sulfate potentiates leukocyte adhesion on cardiac fibroblast by enhancing Vcam-1 and Icam-1 expression[J].Biochim Biophys Acta,2018,1864(53):831-842.
|
[11] |
吴军,文亚红,唐永江.冠心病合并糖尿病患者PCI 术后TLR3,TLR4,IL-10,TNF-α 的表达变化及意义[J].中国循证心血管医学杂志,2018,10(4):114-118.
|
[12] |
祝美珍,苏春寿,刘泰,等.清热化瘀Ⅱ号方对大鼠脑缺血再灌注损伤TLR3,TRAM mRNA 表达的影响[J].中华中医药杂志,2015,15(11):4098-4102.
|
[13] |
赵婷.慢性心力衰竭患者同型半胱氨酸水平与氨基末端B 型钠尿肽原相关性及其临床干预措施[J].中外医学研究,2018,16(17):64-65.
|
[14] |
常红,刘秀琴,张秋业,等.紫癜性肾炎患儿外周血单核细胞Toll 样受体3 和Toll 样受体4 表达的意义[J].中华实用儿科临床杂志,2014,29(5):347-350.
|
[15] |
王媛媛,曹建,邓莉.Toll 样受体3 在大鼠心肌缺血/再灌注损伤中的作用机制[J].中国当代医药,2017,50(31):10-13.
|
[16] |
Schwenkgrub J,Zaremba M,Mirowska-Guzel D,et al.Ibudilast:a nonselective phosphodiesterase inhibitor in brain disorders[J].Postepy Hig Med Dosw (Online),2017,71(20):137-148.
|
[17] |
朱丹,焦晓民,赵涛,等.芪苈强心胶囊对慢性心力衰竭患者血清hs-CRP,TNF-α 及IL-8 水平的影响及其临床疗效[J].现代生物医学进展,2017,17(10):1852-1855.
|
[18] |
董明兴,姜金凤,李宗敏.中西医结合治疗慢性充血性心力衰竭的疗效观察[J].实用中西医结合临床,2016,13(1):12-13.
|
[19] |
徐涛,李方江,陈立锋,等.芪苈强心胶囊对心力衰竭大鼠心室重构的作用及机制研究[J].山东医药,2015,52(32):38-40.
|
|
|
|